Ixekizumab continues to show benefit for nr-axSpA
20 Jul 2020
byAudrey Abella
Use of the monoclonal antibody ixekizumab led to improvements in symptoms, work productivity, and overall functioning and health in patients with nonradiographic axial spondyloarthritis (nr-axSpA), subgroup results of the phase III COAST-X trial have shown.
